Lyell Immunopharma Inc LYEL.OQ LYEL.O is expected to show a fall in quarterly revenue when it reports results on March 9 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Lyell Immunopharma Inc is for a loss of $2.37 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lyell Immunopharma Inc is $38.50, about 74.6% above its last closing price of $22.05
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -2.66 | -2.64 | -2.13 | Beat | 19.4 |
Jun. 30 2025 | -3.52 | -3.58 | -2.89 | Beat | 19.3 |
Mar. 31 2025 | -3.53 | -3.60 | -3.54 | Beat | 1.7 |
Dec. 31 2024 | -2.63 | -3.40 | -4.00 | Missed | -17.6 |
Sep. 30 2024 | -3.79 | -4.00 | -3.40 | Beat | 15 |
Jun. 30 2024 | -4.27 | -4.10 | -3.60 | Beat | 12.2 |
Mar. 31 2024 | -4.49 | -4.20 | -4.80 | Missed | -14.3 |
Dec. 31 2023 | -4.19 | -4.56 | -4.00 | Beat | 12.3 |
This summary was machine generated March 6 at 20:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)